Table of Contents

HK J Paediatr (New Series)
Vol 14. No. 2, 2009

HK J Paediatr (New Series) 2009;14:103-107

Original Article

Long Versus Standard Course Corticosteroid Therapy for Nephrotic Syndrome in Children

ALT Ma, ETL Soo, PC Tong, WM Lai, KC Tse, MC Chiu


Steroid sensitive nephrotic syndrome (SSNS) is a common disease in childhood. Although most children respond to corticosteroid, relapse is a common problem. We aim to compare the effect of 2-month steroid treatment (standard course) according to International Study of Kidney Disease of Children (ISKDC) versus 6-month treatment (long course) on the clinical course of SSNS in a 1.5-year follow up in our centre. Medical records of patients seen from 1997-2006 were reviewed. A total of 46 patients were included in the study (standard course group=22, long course group=24). Patients treated with long course steroid had significantly lower relapse rate (33% versus 75%, p= 0.026) and higher percentage of sustained remission (p=0.0046) than that of standard course. None of our patients had significant growth retardation or hypertension. Therefore, 6-month corticosteroid may be preferable to the standard course for the initial treatment of SSNS in children.

Keyword : Corticosteroids; Relapses; Steroid sensitive nephrotic syndrome

Abstract in Chinese


Nephrotic syndrome (NS) is an important chronic renal disease in childhood.1 Minimal change disease is the most commonly found histology in renal biopsy.2 Although most patients respond to corticosteroids, a majority of patients relapse.2-4 It has been suggested that children who present with a young age at onset or male sex were more likely to have relapses.5,6 Some patients may require prolonged courses of steroids and later cytotoxic agents to maintain remission.7 The optimal dose and duration of steroid therapy for the treatment of NS in children have been investigated.1,8,9 Meta-analysis has concluded that children in their first episode of nephrotic syndrome should be treated for at least three months, with increased benefit up to seven months post treatment compared with 2-month therapy.1 We aimed to compare the effect of 2-month steroid treatment (standard course) according to International Study of Kidney Disease of Children (ISKDC) versus 6-month treatment (long course) on the clinical course of steroid sensitive nephrotic syndrome (SSNS) in our centre.10

Subjects and Methods

Patient Data

The data was collected retrospectively from medical records of children presented with first episode of SSNS seen in paediatric nephrology centre, Princess Margaret Hospital, Hong Kong from January 1997 till July 2006. All records were reviewed for 1.5 years from the completion of steroid treatment. All patients were treated with steroid alone. We have excluded patients who were previously treated, those who suffered from steroid resistant disease (defined as failure to achieve remission with 4-week course of 60 mg/m2/day prednisolone), those who were treated with cytotoxic agents and those who defaulted follow ups in the study period.

Outcome Measures

Percentage of patients with relapses, cumulative rate of sustained remission, total number of relapses, and the height standard deviation score (height SDS) before and after treatment were compared.

Protocol of Prednisolone Treatment for SSNS

Our department employed the ISKDC 2-month standard prednisolone regimen from year 1997 to 2001.10 (Prednisolone 60 mg/m2/day for 4 weeks then 40 mg/m2/alternate day for 4 weeks) We have subsequently changed our protocol to a 6-month regimen from 2002 till now. (Prednisolone 60 mg/m2/day for 4 weeks, then 40 mg/m2/alternate day for 4 weeks and slowly tapering off by 10 mg/m2/alternate day in four months, total course of 6 months) (Figure 1). Our patients were therefore conveniently divided into standard course and long course group.

Definitions of Remission, Relapse and Steroid Dependence

Remission was defined as the disappearance of proteinuria for at least three consecutive days1 (urinary excretion of protein <4 mg/m2/hr or negative to trace from urine dipstick test). Relapse was defined as a reappearance of proteinuria of 2+ of more continued for 3 consecutive days1 (urinary excretion of protein >=40 mg/m2/hr). Relapse was treated with the daily prednisolone does of 60 mg/m2/ day until urine protein became negative for three consecutive days, followed by 40 mg/m2/alternate day for 4 weeks.

Statistical Analysis

Results were expressed as mean ?standard deviation (SD). Comparisons between standard and long course groups were made using unpaired t tests for means of quantitative variables, and Chi-squared or Fisher's exact test for the frequencies of qualitative variables. The cumulative percentage of patients with sustained remission was demonstrated by Kaplan-Meier curve. The height SDS was compared at the beginning and end of treatment with local growth reference.11 All statistical analyses were accomplished using the Statistical Package for the Social Sciences version 12.0 (SPSS 12.0). Statistical significance was considered at the value of p<0.05.


A total of 46 patients were included in our study. Their age of presentation ranged from 2.1 to 15.1 years. There were 32 boys (68.1%) and 14 girls (29.8%). The standard course group consisted of 22 patients (mean age of 5.12, Male to female ratio=17:5). Long course group consisted of 24 patients (mean age of 6.29, male to female ratio=15:9). There was no significant difference between the two groups of patients in terms of number, age of disease onset, sex ratio, and serum parameters (Table 1).

Patients treated with standard course steroid had significantly higher relapse rate at the end of the study (75% vs 33%, p=0.026). Only six patients in the standard course group never relapsed while fifteen patients never relapsed in the long course group. The percentage of patients who remained in sustained remission is significantly higher in the long course group than the standard course group (log rank value=8.03, p=0.0046) (Figure 1). Although the number of relapses during the follow up period (per patient per year) did not differ significantly between the two groups, patients from the standard course group were more likely to relapse more than once in the study period (p=0.017). None of our patients was on anti-hypertensive agents. No significant difference was found in the mean height SDS before and after steroid treatment when comparison was made within the same treatment group, and between the two groups (Tables 2 & 3).

The results from the two groups were integrated in the last part of the study. We aimed to look at the impact on the course of disease by the absence of relapse within the first 6 months post-treatment (Table 3). In our study, 20 patients (43% of the total study population) had relapse within the first 6 months after completing the initial therapy. Thirteen of these 20 children (65% of those who relapsed in the first 6 months) had further relapse in the next 6-12 months. On the other hand, for the remaining 26 patients who did not relapse (57% of the total study population), only seven relapsed in the next 6-12 months (27% of those who did not relapse in the first 6 months) (Odds ratio 5.04, 95% confidence interval 1.42-17.8). Therefore, patients with relapse within the first six months after initial therapy were more likely to relapse in the next 6-12 months.

Figure 1 Standard and long course corticosteroid for treatment of SSNS in children.


Table 1 Clinical and laboratory characteristics of patients

  Standard course Long course Significance
No of patients (n) 22 24 Not significant
M/F 17/5 15/9 Not significant
Age 5.12±3.18 6.92 ±5.57 Not significant
Serum Albumin (g/dl) 15.5±2.41 15.6±4.01 Not significant
Serum creatinine (umol/L ) 42.5±12.5 47.1±18 Not significant


Table 2 Data comparison between the standard and long course groups


Standard course (N=22) Long course (N=24) Significance
No. of patients without relapse 6 15 P=0.026
No. of patients with relapses 16 (75%) 9 (33%) P=0.026
No. of patients with >1 relapses 15 5 P=0.017
Height SDS score      
Before steroid treatment 1.1±3.5 0.5±1.1 Not significant
After steroid treatment 0.8±1.54 0.27±1.04  


Table 3 Influence of the absence of relapses on further course of SSNS


  No. and % of patients who relapse in the following post treatment periods
Course of disease First 6m after treatment Next 6 to 12m after treatment
  No. % No. %
Children with relapse(s) 20/46 43% 13/20 65%
Children without relapse 26/46 56% 7/26 27%


Corticosteroid has been the drug of choice for treatment of SSNS in children.1,8,12 Although more than 90% of children are responsive to steroid therapy, over 70% of patients with SSNS subsequently relapse.1,12 In our cohort, up to 75% of patients in the standard course group relapsed. This result could be related to the limitations of this study and will be discussed later. Nevertheless, we were able to demonstrate that nephrotic children who were treated with long course steroid therapy had fewer relapses, and were more likely to remain in remission (Figure 2). Our findings are consistent with the previous work showing an inverse relation between the risk of relapse and the duration of corticosteroids therapy.1,3,13-17 Therefore, many centres now recommend steroid treatment of at least 12 weeks for better patient outcome.3,16-17 The optimal protocol to treat SSNS, and more so relapsing SSNS, is yet to be defined and studies are underway.5,9 Hopefully, more detailed approach will be available in the near future.

Figure 2 Cumulative rate of children with sustained remission of long course (black line with triangle) vs standard course (grey line with square) steroid therapy.

Steroid is not without side effects. Obesity, striae, hirsutism, osteoporosis, psychiatric disturbances, and cataract are some of the common side effects.13 The occurrence of steroidal side-effects was only partly addressed by this study because of its retrospective nature and incomplete documentation of data. We were only able to conclude that none of our patients in this cohort was on anti-hypertensive agents, and there was no significant difference between the pre and post steroid height SDS in each study group. The degree of steroid toxicity was shown to be proportional to the dose and duration of treatment.7,18 Hodson et al commented that six-month therapy results in less relapse without increase in adverse effects in comparison to three-month therapy.1,18 This view was supported by various authors.8,13 It was opined that the side effects of steroids were reversible or mild if further treatment courses were rarely required subsequently.13 After all, physicians must judge clinically and take the balance between better relapse control and steroid toxicities.

According to APN (Arbeitsgemeinschaft fur Padiatrische Nephrologie) report in 1988, the percentage of patients with frequent relapses in the first 6 months after cessation of steroid was higher with the standard course regimen (61%) than the long course regimen (31%).16 Similar results were shown by Ueda et al and Ehrich & Brodehl in 1988 and 1992 respectively.7,13 Our results and theirs suggested that children with relapse early in their illness continue to have a stronger tendency to relapse throughout their illness than those who did not. It remains, however, unclear if the beneficial effect of long course is solely related to the extended duration of immunosuppression.13 Apart from early relapse after disease onset, the duration of remission period immediately before the most recent relapse was also described to be a risk factor for prediction of relapse.17 Patients having both risk factors may be more likely to have relapsing disease, and hence earlier treatment with immunosuppressants could be considered in selected cases.17

One interesting observation was the great difference between the survival curves of the two groups. This may be an over presentation and deserves explanation. In terms of patients' clinical characteristics, although their serum albumin and creatinine levels showed no significant difference between the two groups, there could still be difference in their disease severity to start with. Limited by the retrospective nature of the study, laboratory parameters such as initial cholesterol level, 24 hour urine protein level, and creatinine clearance were not well documented and therefore no valid statistical analysis could be carried out to compare the two groups of patients. In terms of management practice, despite the presence of a standard steroid protocol in the department, different physicians may have their own preference on dosage adjustments. This contributed to the difference in total cumulative dose of steroids given to patients and hence their outcomes. The failure to document patient's compliance to treatment was another limitation of the study. Therefore, despite the significant findings, we believe that the two groups of patients may represent patients with dissimilar severity of nephrotic syndrome which took cautions to compare.

There are certain limitations to our study. As mentioned, being a retrospective study, data collection was incomplete in some areas. Second, the sample size is relatively small and patient recruitment was not randomised. Moreover, all the data was obtained from a single centre and hence more prone to bias. Patients were recruited from different periods of time, and it was not known if there was change in the histopathological heterogeneity of children with nephrotic syndrome over the years which may contribute to the difference in response to steroid therapy. Last but not least, the follow up period was short and the duration of sustained remission after steroid treatment could not be accurately projected. All these factors may result in bias and should be taken into consideration.

In conclusion, with the limitations and constraints in mind, the 6-month corticosteroid therapy is more likely to provide better rate of sustained remission when compared to the standard ISKDC regimen as the initial management of first episode SSNS. This pilot study sets the scene for future studies to further examine the implication of duration of corticosteroids on the clinical course of nephrotic syndrome in children.


1. Hodson EM, Willis NS, Craig JC. Corticosteroid therapy for nephrotic syndrome in children. Cochrane Database Syst Rev 2007;CD001533.

2. Bagga A, Mantan M. Nephrotic syndrome in children. Indian J Med Res 2005;122:13-28.

3. Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet 2003;362:629-39.

4. Ruth EM, Kemper MJ, Leumann EP, et al. Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome. J Pediatr 2005;147:202-7.

5. Hiraoka M, Tsukahara H, Haruki S, et al. Older boys benefit from higher initial prednisolone therapy for nephrotic syndrome. The West Japan Cooperative Study of Kidney Disease in Children. Kidney Int 2002;58:1247-52.

6. Lewis MA, Baildom EM, Davis N, Houston IB, Postlethwaite RJ. Nephrotic syndrome: from toddlers to twenties. Lancet 1989;1:255-9.

7. Ueda N, Chihara M, Kawaguchi S, et al. Intermittent versus long-term tapering prednisolone for initial therapy in children with idiopathic nephrotic syndrome. J Pediatr 1988;112:122-6.

8. Ksiazek J, Wyszynska T. Short versus long initial prednisone treatment in steroid-sensitive nephrotic syndrome in children. Acta Paediatr 1995;84:889-93.

9. Hiraoka M TH, Matsubara K, Tsurusawa M, et al. A randomised study of Two long courses predinisolone regimens for nephrotic syndrome in children. Am J Kidney Dis 2003;41:1156-62.

10. Abramowicz M, Barnett HL, Edelmann CM Jr, et al. Controlled trial of azathioprine in children with nephrotic syndrome. A report for the international study of kidney disease in children. Lancet 1970;1:959-61.

11. Leung SS, Lau JT, Xu YY, et al. Secular changes in standing height, sitting height and sexual maturation of Chinese--the Hong Kong Growth Study, 1993. Ann Hum Biol 1996;23:297-306.

12. Brodehl J. Conventional therapy for idiopathic nephrotic syndrome in children. Clin Nephrol 1991;35(Suppl 1):S8-15.

13. Ehrich JH, Brodehl J. Long versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Eur J Pediatr 1993;152:357-61.

14. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981;98:561-4.

15. Tarshish P, Tobin JN, Bernstein J, Edelmann CM Jr. Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. J Am Soc Nephrol 1997;8:769-76.

16. Short versus standard prednisone therapy for initial treatment of idiopathic nephrotic syndrome in children. Arbeitsgemeinschaft fur Padiatrische Nephrologie. Lancet 1988;1:380-3.

17. Takeda A, Takimoto H, Mizusawa Y, Simoda M. Prediction of subsequent relapse in children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 2001;16:888-93.

18. Lam CN, Arneil GC. Long-term dwarfing effects of corticosteroid treatment for childhood nephrosis. Arch Dis Child 1968;43:589-94.


This web site is sponsored by Johnson & Johnson (HK) Ltd.
©2022 Hong Kong Journal of Paediatrics. All rights reserved. Developed and maintained by Medcom Ltd.